炎症性肠病患者的疼痛与镇静药物使用:一项全国性人群队列研究
基于临床实践研究数据链,纳入2010年1月至2019年12月新发炎症性肠病成人17388例,分析阿片类、加巴喷丁类和镇静药物的年度处方率。每年超过20%被处方疼痛或镇静药物,阿片类和加巴喷丁类处方率上升,慢性处方和联合处方亦增加,女性、吸烟、诊断时年龄较大、克罗恩病及炎症性关节病、肠易激综合征、纤维肌痛或焦虑/抑郁与慢性或联合处方显著相关。
要点
- 每年超过20%的炎症性肠病患者被处方疼痛或镇静药物。
- 阿片类和加巴喷丁类年度处方率上升,镇静药物保持稳定。
- 女性、吸烟、年龄较大、克罗恩病及部分共病与慢性或联合处方相关。
核心结论
- 相当比例的炎症性肠病患者被处方疼痛和镇静药物,包括长期处方和联合处方;识别高危患者对于优先分配有限资源(如心理治疗)以替代有害处方至关重要。
研究设计与样本
- 使用临床实践研究数据链这一大型全国代表性数据集,分析2010年1月至2019年12月新发炎症性肠病成人患者的总处方、慢性处方(阿片类>90天;镇静药物>28天)及阿片类、加巴喷丁类和镇静药物联合处方的年度患病率;采用多变量回归识别慢性或联合处方的预测因素。
主要发现
- 在17388例个体中,每年超过20%被处方疼痛或镇静药物。
- 阿片类和加巴喷丁类的年度患病率分别从13.6%升至14%和从2.5%升至5.6%,镇静药物患病率保持稳定在8.4%。
- 慢性处方增加:强阿片类从3.6%升至4.6%,弱阿片类从3.6%升至3.7%,镇静药物从4.2%升至4.4%。
- 每年有4.2%至6.9%的个体被联合处方阿片类、加巴喷丁类和/或镇静药物。
- 女性、吸烟、诊断时年龄较大、克罗恩病以及炎症性关节病、肠易激综合征、纤维肌痛或焦虑/抑郁的诊断与阿片类或镇静药物的慢性和/或联合处方显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with inflammatory bowel disease (IBD) often experience pain, mood disturbances, and sleep disruption, which may lead to greater use of pain-relieving and sedative medications compared with the general population. These are associated with increased mortality, paradoxical worsening of pain, and inappropriate IBD treatment discontinuation. Chronic prescribing and co-prescribing increase the risk of respiratory depression, dependence, and overdose. METHODS: Using Clinical Practice Research Datalink, a large nationally representative dataset, we examined the annual prevalence of total, chronic (> 90 days opioids; > 28 days sedatives), and co-prescribed opioids, gabapentinoids and sedatives in adults with incident IBD from January 2010 to December 2019. Multivariable regression identified predictors of chronic or co-prescribing. RESULTS: Among 17,388 individuals, over 20% were prescribed a pain or sedative medication each year. Annual prevalence for opioids and gabapentinoids increased (13.6%-14% and 2.5%-5.6%, respectively) while sedative prevalence remained stable (8.4%). Chronic prescribing increased for strong opioids (3.6%-4.6%), weak opioids (3.6%-3.7%) and sedatives (4.2%-4.4%). Between 4.2% and 6.9% of individuals per year were co-prescribed opioids, gabapentinoids, and/or sedatives. Female sex, smoking, older age at diagnosis, Crohn's disease, and a diagnosis of inflammatory arthropathy, irritable bowel syndrome, fibromyalgia, or anxiety/depression were significantly associated with chronic and/or co-prescriptions of opioids or sedatives. CONCLUSION: A substantial proportion of individuals with IBD are prescribed pain and sedative medications, including long-term and co-prescriptions. Identifying high-risk patients is essential to ensure they are prioritised for limited resources, such as psychological therapies, as alternatives to harmful prescriptions.
引用
- Baillie S, Saxena S, Jayasooriya N, et al. Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. Aliment Pharmacol Ther. 2025. PMID: 40599116. doi:10.1111/apt.70247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。